Your browser is no longer supported. Please, upgrade your browser.
SRNE Sorrento Therapeutics, Inc. daily Stock Chart
SRNE [NASD]
Sorrento Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.72 Insider Own34.21% Shs Outstand182.61M Perf Week22.06%
Market Cap1.52B Forward P/E- EPS next Y-0.93 Insider Trans0.06% Shs Float147.65M Perf Month85.62%
Income-249.20M PEG- EPS next Q-0.23 Inst Own16.50% Short Float27.94% Perf Quarter188.91%
Sales33.00M P/S46.06 EPS this Y-14.80% Inst Trans7.34% Short Ratio1.25 Perf Half Y114.52%
Book/sh0.55 P/B13.03 EPS next Y-12.00% ROA-44.50% Target Price- Perf Year197.30%
Cash/sh- P/C- EPS next 5Y37.00% ROE-322.50% 52W Range1.39 - 10.00 Perf YTD111.98%
Dividend- P/FCF- EPS past 5Y-11.10% ROI-91.30% 52W High-28.35% Beta3.15
Dividend %- Quick Ratio0.50 Sales past 5Y52.40% Gross Margin62.50% 52W Low415.47% ATR0.56
Employees310 Current Ratio0.60 Sales Q/Q26.20% Oper. Margin- RSI (14)73.85 Volatility9.71% 10.13%
OptionableYes Debt/Eq1.98 EPS Q/Q59.60% Profit Margin- Rel Volume0.63 Prev Close6.85
ShortableYes LT Debt/Eq1.81 Earnings- Payout- Avg Volume32.88M Price7.16
Recom2.00 SMA2035.82% SMA5064.08% SMA200136.49% Volume20,429,358 Change4.60%
May-26-20Initiated Dawson James Buy $24
Oct-07-19Initiated JMP Securities Mkt Outperform $21
Jun-28-18Initiated B. Riley FBR, Inc. Buy $14.25
Jan-16-18Reiterated H.C. Wainwright Buy $20 → $30
May-22-17Reiterated Rodman & Renshaw Buy $30 → $20
May-22-17Reiterated FBR & Co. Outperform $13 → $9
Oct-03-16Initiated ROTH Capital Buy
Apr-06-16Reiterated FBR Capital Outperform $21 → $16
Mar-16-16Reiterated FBR Capital Outperform $22 → $21
Dec-22-15Initiated FBR Capital Outperform $22
Dec-07-15Resumed Rodman & Renshaw Buy $45
Aug-03-15Resumed MLV & Co Buy $34
Jul-29-15Reiterated Brean Capital Buy $17 → $26
May-28-15Initiated Brean Capital Buy $17
Mar-17-15Reiterated H.C. Wainwright Buy $13 → $20
Oct-02-14Initiated H.C. Wainwright Buy $11
Jun-19-14Initiated MLV & Co Buy $9
Dec-03-13Initiated Aegis Capital Buy $40
Nov-21-13Initiated CRT Capital Buy $11
Jul-06-20 08:19PM  
06:48PM  
06:43PM  
01:30AM  
Jul-03-20 03:45PM  
10:18AM  
Jul-01-20 08:00PM  
06:52PM  
06:45PM  
04:25PM  
04:00PM  
01:40PM  
01:00PM  
12:06PM  
10:25AM  
09:44AM  
Jun-30-20 09:50PM  
09:30PM  
08:10PM  
Jun-29-20 11:45AM  
10:22AM  
08:45AM  
08:00AM  
Jun-26-20 05:48PM  
04:48PM  
10:45AM  
10:12AM  
Jun-24-20 06:30PM  
06:07PM  
06:07PM  
06:00PM  
12:00PM  
11:00AM  
06:30AM  
Jun-23-20 11:58PM  
07:40PM  
06:50PM  
Jun-22-20 05:30PM  
04:50PM  
03:30PM  
02:55PM  
01:45PM  
01:09PM  
01:20AM  
Jun-20-20 08:36PM  
Jun-19-20 01:20PM  
12:01PM  
11:42AM  
10:46AM  
10:00AM  
08:52AM  
Jun-18-20 01:00PM  
Jun-17-20 07:10PM  
05:00PM  
03:51PM  
01:19PM  
12:15PM  
12:08PM  
Jun-16-20 05:05PM  
04:00PM  
06:51AM  
Jun-15-20 03:25PM  
03:10PM  
02:55PM  
07:45AM  
06:20AM  
Jun-14-20 07:45AM  
01:57AM  
Jun-13-20 01:40PM  
Jun-12-20 09:35PM  
07:55PM  
04:12PM  
03:21PM  
03:00PM  
01:50PM  
01:09PM  
06:50AM  
Jun-11-20 01:50PM  
01:08PM  
12:58PM  
11:31AM  
09:45AM  
09:00AM  
08:12AM  
06:20AM  
05:47AM  
Jun-10-20 10:33PM  
09:57PM  
09:35PM  
05:15PM  
04:00PM  
03:50PM  
02:45PM  
02:40PM  
01:38PM  
06:44AM  
Jun-09-20 09:09AM  
07:02AM  
Jun-08-20 05:33PM  
01:35PM  
Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Robin LDirectorMar 05Buy2.2740,00090,89660,000Mar 05 01:58 PM